These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 21646435)
1. Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. Kosaka K; Sakai N; Endo Y; Fukuhara Y; Tsuda-Tsukimoto M; Ohtsuka T; Kino I; Tanimoto T; Takeba N; Takahashi M; Kume T Drug Metab Dispos; 2011 Sep; 39(9):1495-502. PubMed ID: 21646435 [TBL] [Abstract][Full Text] [Related]
2. Intestinal glucuronidation metabolism may have a greater impact on oral bioavailability than hepatic glucuronidation metabolism in humans: a study with raloxifene, substrate for UGT1A1, 1A8, 1A9, and 1A10. Mizuma T Int J Pharm; 2009 Aug; 378(1-2):140-1. PubMed ID: 19486934 [TBL] [Abstract][Full Text] [Related]
3. Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9. Kishi N; Takasuka A; Kokawa Y; Isobe T; Taguchi M; Shigeyama M; Murata M; Suno M; Hanioka N Xenobiotica; 2016; 46(4):289-95. PubMed ID: 26247833 [TBL] [Abstract][Full Text] [Related]
4. Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance. Kemp DC; Fan PW; Stevens JC Drug Metab Dispos; 2002 Jun; 30(6):694-700. PubMed ID: 12019197 [TBL] [Abstract][Full Text] [Related]
5. Method for predicting human intestinal first-pass metabolism of UGT substrate compounds. Furukawa T; Yamano K; Naritomi Y; Tanaka K; Terashita S; Teramura T Xenobiotica; 2012 Oct; 42(10):980-8. PubMed ID: 22540538 [TBL] [Abstract][Full Text] [Related]
6. Quantitative prediction of intestinal glucuronidation of drugs in rats using in vitro metabolic clearance data. Furukawa T; Nakamori F; Tetsuka K; Naritomi Y; Moriguchi H; Yamano K; Terashita S; Teramura T Drug Metab Pharmacokinet; 2012; 27(2):171-80. PubMed ID: 21970858 [TBL] [Abstract][Full Text] [Related]
7. Raloxifene glucuronidation in human intestine, kidney, and liver microsomes and in human liver microsomes genotyped for the UGT1A1*28 polymorphism. Trdan Lusin T; Trontelj J; Mrhar A Drug Metab Dispos; 2011 Dec; 39(12):2347-54. PubMed ID: 21937736 [TBL] [Abstract][Full Text] [Related]
8. Effect of intestinal glucuronidation in limiting hepatic exposure and bioactivation of raloxifene in humans and rats. Dalvie D; Kang P; Zientek M; Xiang C; Zhou S; Obach RS Chem Res Toxicol; 2008 Dec; 21(12):2260-71. PubMed ID: 19548350 [TBL] [Abstract][Full Text] [Related]
9. The impact of glucuronidation on the bioactivation and DNA adduction of the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in vivo. Malfatti MA; Ubick EA; Felton JS Carcinogenesis; 2005 Nov; 26(11):2019-28. PubMed ID: 15944213 [TBL] [Abstract][Full Text] [Related]
10. Age-and Region-Dependent Disposition of Raloxifene in Rats. Du T; Sun R; Etim I; Zheng Z; Liang D; Hu M; Gao S Pharm Res; 2021 Aug; 38(8):1357-1367. PubMed ID: 34322833 [TBL] [Abstract][Full Text] [Related]
11. Disposition of flavonoids via enteric recycling: UDP-glucuronosyltransferase (UGT) 1As deficiency in Gunn rats is compensated by increases in UGT2Bs activities. Wang SW; Kulkarni KH; Tang L; Wang JR; Yin T; Daidoji T; Yokota H; Hu M J Pharmacol Exp Ther; 2009 Jun; 329(3):1023-31. PubMed ID: 19264971 [TBL] [Abstract][Full Text] [Related]
12. Prediction of hepatic and intestinal glucuronidation using in vitro-in vivo extrapolation. Naritomi Y; Nakamori F; Furukawa T; Tabata K Drug Metab Pharmacokinet; 2015 Feb; 30(1):21-9. PubMed ID: 25760528 [TBL] [Abstract][Full Text] [Related]
13. Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Miles KK; Kessler FK; Smith PC; Ritter JK Drug Metab Dispos; 2006 Sep; 34(9):1632-9. PubMed ID: 16790558 [TBL] [Abstract][Full Text] [Related]
14. Glucuronidation and excretion of nonylphenol in perfused rat liver. Daidoji T; Inoue H; Kato S; Yokota H Drug Metab Dispos; 2003 Aug; 31(8):993-8. PubMed ID: 12867487 [TBL] [Abstract][Full Text] [Related]
15. Differences between human and rat intestinal and hepatic bisphenol A glucuronidation and the influence of alamethicin on in vitro kinetic measurements. Mazur CS; Kenneke JF; Hess-Wilson JK; Lipscomb JC Drug Metab Dispos; 2010 Dec; 38(12):2232-8. PubMed ID: 20736320 [TBL] [Abstract][Full Text] [Related]
16. Glucuronidation of zearalenone, zeranol and four metabolites in vitro: formation of glucuronides by various microsomes and human UDP-glucuronosyltransferase isoforms. Pfeiffer E; Hildebrand A; Mikula H; Metzler M Mol Nutr Food Res; 2010 Oct; 54(10):1468-76. PubMed ID: 20397195 [TBL] [Abstract][Full Text] [Related]
17. Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data. Nakamori F; Naritomi Y; Hosoya K; Moriguchi H; Tetsuka K; Furukawa T; Kadono K; Yamano K; Terashita S; Teramura T Drug Metab Dispos; 2012 Sep; 40(9):1771-7. PubMed ID: 22685216 [TBL] [Abstract][Full Text] [Related]
18. Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Gill KL; Houston JB; Galetin A Drug Metab Dispos; 2012 Apr; 40(4):825-35. PubMed ID: 22275465 [TBL] [Abstract][Full Text] [Related]
19. Species differences in intestinal glucuronidation activities between humans, rats, dogs and monkeys. Furukawa T; Naritomi Y; Tetsuka K; Nakamori F; Moriguchi H; Yamano K; Terashita S; Tabata K; Teramura T Xenobiotica; 2014 Mar; 44(3):205-16. PubMed ID: 23962030 [TBL] [Abstract][Full Text] [Related]
20. Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform. Kaji H; Kume T Drug Metab Dispos; 2005 Mar; 33(3):403-12. PubMed ID: 15608137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]